{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.6","upperLimit":"92.5","value":"87.2"},{"groupId":"OG001","lowerLimit":"81.7","upperLimit":"94.3","value":"89.7"}]}],"title":"12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.5","upperLimit":"89.9","value":"83.8"},{"groupId":"OG001","lowerLimit":"75.2","upperLimit":"91.2","value":"85.0"}]}],"title":"18 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"Estimated percentage of participants who were event-free based on Kaplan-Meier method","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants diagnosed with WM with mutated MYD88 gene received 420 mg ibrutinib once daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG000","title":"Arm A: Ibrutinib"},{"description":"Participants diagnosed with WM with mutated MYD88 gene received 160 mg zanubrutinib twice daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG001","title":"Arm B: Zanubrutinib"}],"paramType":"NUMBER","populationDescription":"ITT Analysis Set","reportingStatus":"POSTED","timeFrame":"12 and 18 months from the date of randomization (up to approximately 2 years and 7 months)","title":"PFS as Assessed by IRC: Event-Free Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}